Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Whole-Body Cryotherapy and Isokinetic Performance After Exercise-Induced Fatigue (WBC-ISO)

1 de junio de 2026 actualizado por: Zeynep Koluman, Biruni University

Effect of Whole-Body Cryotherapy on Isokinetic Performance After Exercise-Induced Fatigue

This randomized crossover study investigated the effects of whole-body cryotherapy (WBC) on isokinetic knee performance following running-induced fatigue in physically active healthy male university students. Participants completed two recovery conditions, WBC and passive rest, on separate days following a standardized treadmill fatigue protocol. Knee extension and flexion strength were assessed using an isokinetic dynamometer at angular velocities of 60°/s and 240°/s. In addition, blood pressure, heart rate, oxygen saturation, and perceived fatigue responses were monitored throughout the recovery period. The study aimed to determine whether WBC improves post-exercise recovery and lower-extremity muscle performance compared with passive rest.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

This study was designed to investigate the effects of whole-body cryotherapy (WBC) on recovery and isokinetic muscle performance following exercise-induced fatigue in physically active healthy male university students. Exercise-induced fatigue is associated with reduced muscle force production, impaired performance, and increased injury risk. Various recovery strategies have been used to minimize these negative effects, and WBC has gained increasing attention in sports medicine because of its potential physiological and neuromuscular recovery benefits.

The study used a randomized within-subject crossover design in which participants completed two recovery conditions, WBC and passive rest, on separate days following a standardized treadmill-based fatigue protocol. During the WBC condition, participants were exposed to a two-stage cryogenic chamber consisting of an adaptation chamber at -30°C followed by a main chamber at -85°C. Passive rest sessions were performed under the same laboratory conditions without cryotherapy exposure.

Primary outcome measures included isokinetic knee extension and flexion performance assessed at angular velocities of 60°/s and 240°/s using an isokinetic dynamometer. Peak torque and body mass-normalized peak torque values were analyzed for both dominant and non-dominant lower extremities. Secondary outcome measures included systolic and diastolic blood pressure, heart rate, oxygen saturation, and perceived fatigue responses measured throughout the recovery period.

The aim of the study was to determine whether WBC provides superior recovery effects compared with passive rest following running-induced acute fatigue.

Tipo de estudio

Intervencionista

Inscripción (Actual)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Istanbul
      • Istanbul, Istanbul, Turquía (Türkiye), 34000
        • Istanbul University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Descripción

Inclusion Criteria:

  • Healthy male participants aged 18-30 years with no exercise limitation
  • No history of knee or lower-extremity injury requiring physiotherapy or surgical intervention
  • No current lower-extremity pain
  • No limitation in lower-extremity range of motion
  • No chronic disease
  • No mental or psychological disorder

Exclusion Criteria:

  • Presence of cardiovascular disease
  • Presence of respiratory disease
  • History of cold allergy
  • Presence of a tumor-related disease
  • Presence of a viral or bacterial infection
  • Diagnosis of Raynaud's disease
  • Presence of claustrophobia

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Whole-Body Cryotherapy
Participants underwent whole-body cryotherapy following the running-induced fatigue protocol.
Participants underwent whole-body cryotherapy following a standardized running-induced fatigue protocol. The intervention was performed in a two-stage cryogenic chamber consisting of a 30-second adaptation phase at -30°C followed by a 3-minute exposure at -85°C.
Sin intervención: Passive Rest
Participants completed passive seated rest following the running-induced fatigue protocol.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Peak Torque During Knee Extension and Flexion
Periodo de tiempo: Immediately after the 30-minute recovery period
Assessment of isokinetic knee extension and flexion peak torque at 60°/s and 240°/s following whole-body cryotherapy and passive rest recovery conditions.
Immediately after the 30-minute recovery period
Peak Torque Normalized to Body Mass
Periodo de tiempo: Immediately after the 30-minute recovery period
Assessment of body mass-normalized peak torque values during isokinetic knee extension and flexion testing at 60°/s and 240°/s.
Immediately after the 30-minute recovery period

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Heart Rate
Periodo de tiempo: Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Assessment of heart rate responses throughout the recovery period following exercise-induced fatigue.
Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Blood Pressure
Periodo de tiempo: Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Assessment of systolic and diastolic blood pressure responses throughout the recovery period.
Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Oxygen Saturation
Periodo de tiempo: Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Assessment of peripheral oxygen saturation during the recovery period.
Baseline, immediately after exercise, and every 5 minutes during the 30-minute recovery period
Perceived Fatigue
Periodo de tiempo: Immediately after exercise, 5 minutes, and 10 minutes after exercise
Assessment of perceived fatigue using the Borg Rating of Perceived Exertion (RPE) Scale (6-20 points). Scores range from 6 (no exertion) to 20 (maximal exertion), with higher scores indicating greater perceived fatigue and exertion.
Immediately after exercise, 5 minutes, and 10 minutes after exercise

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de septiembre de 2024

Finalización primaria (Actual)

1 de mayo de 2025

Finalización del estudio (Actual)

1 de mayo de 2025

Fechas de registro del estudio

Enviado por primera vez

24 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de mayo de 2026

Publicado por primera vez (Actual)

1 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de junio de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2024/1567

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir